Biosimilars Are Making Inroads In U.S., But It’s Still A Bumpy RideBy Press Room4 November 2024 Biosimilars offer clinically effective treatment alternatives to branded reference drugs at a lower cost. These products are making inroads in…
Medicare Patient Access To Humira-Referenced Biosimilars Still Falls ShortBy Press Room5 February 2024 According to a federal government Medicare Payment Advisory Commission report published last month, more than 40% of Medicare beneficiaries still…